Clinical trial
A Study to Examine the Effects of an Experimental Drug on Women With Breast…
NCT00399802 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00399802 |
|---|---|
| Title | A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED) |
| Official title | A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women With Breast Cancer and Established Bone Metastases (MBD) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Metastatic Bone Disease |
| Intervention type | Drug |
| Interventions | ZA, Odanacatib, Odanacatib matching placebo, ZA matching placebo |
| Enrollment | 43 |
| Start date | Nov 16, 2006 |
| Primary completion | Dec 5, 2007 |
| Completion | Dec 5, 2007 |
| First posted | Nov 15, 2006 |
| Last update posted | Aug 16, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: